Bacteriotherapy to treat non-alcoholic fatty liver disease

肥胖在英国已达到流行病的程度。超过60%的英国成年人肥胖或超重，三分之一的人患有肝脏脂肪变性，脂肪在肝脏中的积累被认为是非酒精性脂肪性肝病（NAFLD）的早期阶段NAFLD与肠道微生物组的深刻变化和促进肠道通透性有关，肠道通透性允许细菌产物从肠道泄漏到肝脏，在肝脏中它们导致炎症和疾病目前没有许可的药物来治疗NAFLD，因此迫切需要找到新的治疗方法。基于其对疾病进展的贡献，调节微生物组作为治疗NAFLD的治疗方法显示出巨大的前景。

Obesity has reached epidemic proportions in the UK. Over 60% of UK adults are either obese or overweight, and one in three has liver steatosis, an accumulation of fat in the liver considered to be an early stage of non-alcoholic fatty liver disease (NAFLD).NAFLD associates with profound changes in the gut microbiome and promoting intestinal permeability that allows the leak of bacteria products from the intestine to the liver where they contribute to inflammation and disease progression.There are currently no licenced drugs to treat NAFLD, so the need to find new therapeutics is urgent. Based on its contribution to disease progression, modulation of the microbiome as a therapeutic approach for treating NAFLD shows great promise.